With the development of CDK4/6 inhibitors, PI3Kinase inhibitors, checkpoint inhibitors, and antibody-drug conjugates, there are many developing treatment options available to metastatic breast cancer patients, thus rendering application of these results unclear in the current breast cancer treatment landscape. Here, CDK4 is linked to breast cancer.